CN108251378B - A kind of interstital stem cell excretion body and its preparation method and application being overexpressed PTGDS gene - Google Patents
A kind of interstital stem cell excretion body and its preparation method and application being overexpressed PTGDS gene Download PDFInfo
- Publication number
- CN108251378B CN108251378B CN201810060438.7A CN201810060438A CN108251378B CN 108251378 B CN108251378 B CN 108251378B CN 201810060438 A CN201810060438 A CN 201810060438A CN 108251378 B CN108251378 B CN 108251378B
- Authority
- CN
- China
- Prior art keywords
- ptgds
- stem cell
- overexpressed
- interstital stem
- excretion body
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000029142 excretion Effects 0.000 title claims abstract description 115
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 88
- 101150020237 PTGDS gene Proteins 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 101001135402 Homo sapiens Prostaglandin-H2 D-isomerase Proteins 0.000 claims abstract description 75
- 102100033279 Prostaglandin-H2 D-isomerase Human genes 0.000 claims abstract description 73
- 210000004027 cell Anatomy 0.000 claims abstract description 60
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 23
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 22
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 22
- 238000001890 transfection Methods 0.000 claims abstract description 20
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 7
- 239000006228 supernatant Substances 0.000 claims description 44
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims description 28
- 229930006000 Sucrose Natural products 0.000 claims description 23
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 23
- 239000005720 sucrose Substances 0.000 claims description 23
- 239000012141 concentrate Substances 0.000 claims description 19
- 238000005119 centrifugation Methods 0.000 claims description 18
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 14
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 14
- 230000003321 amplification Effects 0.000 claims description 14
- 239000012894 fetal calf serum Substances 0.000 claims description 14
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 10
- 210000003463 organelle Anatomy 0.000 claims description 10
- 238000000432 density-gradient centrifugation Methods 0.000 claims description 9
- 239000001963 growth medium Substances 0.000 claims description 9
- 239000012679 serum free medium Substances 0.000 claims description 9
- 230000007910 cell fusion Effects 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims 1
- 230000012010 growth Effects 0.000 abstract description 9
- 238000013508 migration Methods 0.000 abstract description 8
- 230000005012 migration Effects 0.000 abstract description 8
- 230000004614 tumor growth Effects 0.000 abstract description 3
- 238000012986 modification Methods 0.000 description 31
- 230000004048 modification Effects 0.000 description 31
- 230000002018 overexpression Effects 0.000 description 20
- 238000000034 method Methods 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 239000000047 product Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 5
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 102100037904 CD9 antigen Human genes 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 4
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 4
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 102100025222 CD63 antigen Human genes 0.000 description 3
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 239000012578 cell culture reagent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 2
- 238000002331 protein detection Methods 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 description 1
- 102000009389 Prostaglandin D receptors Human genes 0.000 description 1
- 102100033076 Prostaglandin E synthase Human genes 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 108090000748 Prostaglandin-E Synthases Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y503/00—Intramolecular oxidoreductases (5.3)
- C12Y503/99—Other intramolecular oxidoreductases (5.3.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810060438.7A CN108251378B (en) | 2018-01-22 | 2018-01-22 | A kind of interstital stem cell excretion body and its preparation method and application being overexpressed PTGDS gene |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810060438.7A CN108251378B (en) | 2018-01-22 | 2018-01-22 | A kind of interstital stem cell excretion body and its preparation method and application being overexpressed PTGDS gene |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108251378A CN108251378A (en) | 2018-07-06 |
CN108251378B true CN108251378B (en) | 2019-09-10 |
Family
ID=62742060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810060438.7A Active CN108251378B (en) | 2018-01-22 | 2018-01-22 | A kind of interstital stem cell excretion body and its preparation method and application being overexpressed PTGDS gene |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108251378B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112852708A (en) * | 2019-11-28 | 2021-05-28 | 中国科学院大连化学物理研究所 | Method for establishing in-vitro brain tumor from hiPSCs |
CN113088496A (en) * | 2021-03-19 | 2021-07-09 | 广州远想生物科技有限公司 | EGF mesenchymal stem cell exosome and preparation method and application thereof |
CN113521294A (en) * | 2021-06-22 | 2021-10-22 | 姜海涛 | Stomach targeting drug-loaded exosome and application and drug for treating stomach diseases |
CN114540294A (en) * | 2022-03-14 | 2022-05-27 | 上海交通大学 | Preparation and application of stem cell exosome for delivering gene drugs to tumor site |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101890050B (en) * | 2010-07-14 | 2012-07-04 | 江苏大学 | Human umbilical cordmesenchymal stem cell-derived exosome and application thereof |
CN104490931B (en) * | 2014-12-17 | 2018-08-21 | 江苏大学 | The application of the exosome treatment skin injuries of people's umbilical cord mesenchymal stem cells secretion |
CN106619651A (en) * | 2016-12-23 | 2017-05-10 | 江苏大学 | Application of PGD2 (prostaglandin D2) in preparation of drug for treating stomach cancer |
-
2018
- 2018-01-22 CN CN201810060438.7A patent/CN108251378B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN108251378A (en) | 2018-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108251378B (en) | A kind of interstital stem cell excretion body and its preparation method and application being overexpressed PTGDS gene | |
CN108103017B (en) | The application of the isolation and purification method and people's umbilical cord mesenchymal stem cells excretion body of people's umbilical cord mesenchymal stem cells excretion body | |
CN106591306B (en) | Application of the siRNA of targeting interference tumour PTN-PTPRZ1 access in immunotherapy of tumors | |
CN103911383B (en) | Be suitable for transformation human acid fibroblast growth factor gene that domestic natural silk gland expresses and expression system and application | |
HUE025948T2 (en) | Method for inhibiting metastasis in a stem cell fusion model of carcinogenesis | |
CN105368859A (en) | Chimeric antigen receptor hCD87-CAR, lentivirus carrying hCD87-CAR gene structure, plasmid and application of chimeric antigen receptor hCD87-CAR | |
CN107916253A (en) | A kind of preparation method of mescenchymal stem cell for expressing people source immuno-stimulator LIGHT and obtained MSC L cells | |
CN102596234B (en) | Dendritic cell vaccine for the tumor expressing asparaginyl--B-hydroxylase | |
CN114209814B (en) | Application of TNFSF15 protein in promoting differentiation of bone marrow stem cells into macrophages and expansion | |
CN109402062A (en) | Application of the ZIP1 gene in the product that preparation inhibits apoptosis of mesenchymal stem cell | |
CN101353646A (en) | Telomerase immortalized human fetal forebrain neural precursor cell line and construction method thereof | |
CN101003792A (en) | Constructing 9LLUC cell strain of expressing luciferase stably, and application | |
CN106148276A (en) | Application in the medicine of preparation treatment nerve degenerative diseases for the mescenchymal stem cell | |
CN107217041A (en) | DC cells and T cells with antigenic specificity with high antigen presentation and its preparation method and application | |
CN112251410A (en) | Mouse-derived gastric cancer cell line NCCG1, and establishment method and application thereof | |
CN107022004A (en) | A kind of polypeptide of targets neoplastic cells and its application | |
CN101213954B (en) | Method for acquirement immunological tolerance birds | |
CN100465279C (en) | Prepn and application of epiderm or hair follicle stem cell from souce of human early embryo | |
CN113817777B (en) | Congenital giant black nevus benign tumor cell line from human and construction method thereof | |
CN108486153A (en) | The application and method of FGF2 and 1 fusion of TGF-β in promoting silk cell-proliferation activity and anti-inflammatory properties | |
CN111575384B (en) | Application of human GLT8D1 gene in clinical diagnosis and treatment of tumor | |
CN103789280A (en) | Tumour specific antigen HAAH carboxyl terminal protein preparation technology and application thereof in cancer diagnosis | |
JP5154641B2 (en) | Method for producing tumor vaccine based on endothelial cell surface antigen | |
CN107460170A (en) | The foundation and its application of Pituitary adenoma cell system | |
CN114134181B (en) | Expression unit, recombinant lentivirus expression vector, recombinant lentivirus, and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200427 Address after: 300450 room 801, building 22, No. 59, Kangtai Avenue, Binhai Science Park, Binhai New Area, Tianjin Patentee after: Tianjiu regenerative medicine (Tianjin) Technology Co.,Ltd. Address before: 212000 No. 301, Xuefu Road, Zhenjiang, Jiangsu Patentee before: JIANGSU University |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address |
Address after: 300452 building 20, Green Valley Health Industrial Park, No. 59, Kangtai Avenue, Binhai Science Park, high tech Zone, Binhai New Area, Tianjin Patentee after: Jiutian Lanyue Biotechnology (Tianjin) Co.,Ltd. Country or region after: China Address before: Room 801, Building 22, No. 59 Kangtai Avenue, Binhai Science and Technology Park, Binhai New Area, Tianjin, 300450 Patentee before: Tianjiu regenerative medicine (Tianjin) Technology Co.,Ltd. Country or region before: China |
|
CP03 | Change of name, title or address |